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understood syndrome, that can be defined as the 
presence of 10-99 synchronous adenomas in the large 
bowel, and it is considered a phenotypic variant of 
familial adenomatous polyposis (FAP). This definition 
has the advantage of simplicity, but it may include 
sporadic multiple adenomas of the large bowel at an 
extreme, or FAP cases on the other side. AAP shows a 
milder phenotype than FAP, with an older age of onset 
of adenomas and cancer, and less frequent extracolonic 
manifestations. AAP may be diagnosed as a single 
case in a family or, less frequently, it may be present 
in other family members, and it shows distinct pattern 
of inheritance. In less than 50% of cases, it may be 
caused by adenomatous polyposis coli (APC) or MUTYH 
mutations, referred to as APC -associated polyposis, 
inherited as an autosomal dominant trait, or MUTYH-
associated polyposis, which shows an autosomal 
recessive mechanism of inheritance, respectively. 
Surveillance should rely on colonoscopy at regular 
intervals, with removal of adenomas and careful 
histological examination. When removal of polyps is not 
possible or advanced lesions are observed, the surgical 
approach is mandatory, being subtotal colectomy with 
ileo-rectal anastomosis the treatment of choice. Studies 
on this syndrome are lacking, and controversies are still 
present on many issues, thus, other clinical and genetic 
studies are requested.
Key words: Attenuated adenomatous polyposis; Genetic 
testing; Surveillance; Attenuated familial adenomatous 
polyposis; Adenomatous polyposis coli; MUTYH
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Attenuated adenomatous polyposis is a poorly 
understood syndrome, which may be defined as the 
presence of 10-99 synchronous adenomas in the large 
bowel, when at least 50% of the polyps removed are 
adenomatous. It is a variant of Familial Adenomatous 
Polyposis with a milder phenotype. In less than 50% 
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Abstract
Attenuated adenomatous polyposis (AAP) is a poorly 
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of cases, it is caused by adenomatous polyposis coli 
(APC ) or MUTYH  mutations, and less frequently by 
other genes. Surveillance should rely on colonoscopy at 
regular intervals, with removal of adenomas and careful 
histological examination. If removal of all polyps is not 
possible or advanced lesions are observed, the surgical 
treatment is mandatory.
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INTRODUCTION
Familial adenomatous polyposis (FAP) is a disease 
characterized by the presence of at least 100 adenomas 
of the large bowel, several extracolonic manifestations, 
and it is inherited as an autosomal dominant trait[1]. It is 
caused by constitutional mutations in the adenomatous 
polyposis coli (APC) gene[2,3], and, less frequently, 
by mutations in the MUTYH gene[4]. Attenuated 
familial adenomatous polyposis (AFAP) is considered 
a phenotypic variant of FAP, whose main feature 
is the presence in the large bowel of less than 100 
synchronous adenomas[5]. “Attenuated” also means that 
the disease has a milder phenotype than the classical 
FAP. Indeed, patients with AFAP develop adenomas and 
cancer at an older age, and extracolonic manifestations 
are less frequent than in FAP[5,6]. Moreover, only one 
individual is affected in most families[7]. Nowadays AFAP 
may be included in the broad category of adenomatous 
polyposis syndromes[8]. 
The first approach to an attenuated adenomatous 
polyposis (AAP) should be clinical, and it is extremely 
important for the further management of the disease. 
The first step for a correct evaluation of patients with 
an intestinal polyposis must be a careful collection 
of the family history of cancers and premalignant 
lesions of the gastrointestinal tract, in order to get an 
estimate of the risk of an inherited predisposition to 
cancer. Particular attention should be paid to vertical 
transmission of the disease (from a generation to the 
next), sibling aggregation, and age at diagnosis of 
cancers in the family, especially for first- and second-
degree relatives, although very often we are dealing 
with single cases in a family. Another milestone in 
the management is the particular attention that 
should be put on the histology of polyps removed in 
the large bowel. Polyps are usually adenomas, but 
it is not infrequent to find other histological variants 
(hyperplastic, serrated, hamartomatous, juvenile, or 
mixed), sometimes associated with adenomas. It is 
conceivable to define an adenomatous polyposis when 
more than 50% of polyps are adenomas, otherwise 
other polyposis syndromes should be taken into 
account[9]. Then, relying on the familial pedigree and 
on the characteristics of the individual phenotype of 
the proband, genetic testing for a germline mutation 
should be proposed to the proband, or to the most 
informative family members, when appropriate. In the 
case of attenuated  adenomatous polyposis, firstly APC 
and MUTYH mutations should be searched for[8].
Indeed, constitutional mutations in APC or MUTYH 
genes were found in a large fraction of patients with 
AFAP[9-11]. Accordingly, now the term APC-associated 
polyposis (AFAP) can be more appropriately used 
when the APC gene is mutated, as in the classical 
FAP, whereas MUTYH-associated polyposis (MAP) is 
preferred when MUTYH mutations are found. However, 
many patients with AAP remains “genetic orphans”, 
because at present, no constitutional mutation can be 
demonstrated[12,13]. Moreover, mutations in other genes 
can cause rare forms of attenuated polyposis[14].
As mentioned above, there is still controversy also 
on the morphology of polyps that should be included 
in the definition of attenuated polyposis. In fact, 
according to some authors, hyperplastic or serrated 
polyposis should be included in this category[15,16], 
considering the risk of developing colorectal cancer in 
these forms of intestinal polyposis[17]. Other polyposes 
have peculiar morphologic characteristics that allow to 
classify them as Hamartomatous polyposis syndromes 
(Peutz-Jeghers syndrome, Juvenile polyposis, and 
Cowden syndrome). 
Thus, the picture is far to be completely elucidated, 
and, despite attempts to refine diagnostic accuracy, 
AFAP still remains poorly understood and defined. 
We think that, before proceeding toward the genetic 
diagnosis, it is mandatory to try to reach a useful 
definition of the syndrome that we prefer to refer to 
as AAP. Probably one possible definition is to consider 
as AAP any patient with synchronous adenomas of 
the large bowel ranging between 10 and 99, not 
considering age of onset, other clinical features, or 
formal and molecular genetics. Of course this definition 
is totally clinical, and, as all definitions, it reflects only 
part of the truth. For example, near the upper and 
lower limits of 10 and 99 adenomas it is impossible 
to sharply cut off sporadic multiple adenomas for 
the lower limit, and classical FAP for the upper. 
Moreover, we do not know whether the development 
of further metachronous adenomas during surveillance 
of patients may change the definition and the 
management of the syndrome. Another controversial 
issue is the presence in the family of other patients 
with adenomas or cancer[10]. However this definition 
has the advantage of simplicity, and it allows to have a 
solid ground on which rely for the genetic and clinical 
management of affected patients and family members. 
Another issue is the fraction of adenomas on the total 
number of polyps necessary to define an adenomatous 
polyposis. We think that at least 50% histologically 
confirmed adenomas are necessary for the definition 
of AAP[9].
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Since the definition is unclear and there is no 
real consensus, incidence and frequency of AAP are 
difficult to establish. Frequency may be estimated to 
be less than 15% of all adenomatous polyposes, but 
a systematic search for AAP has never been carried 
out. As mentioned above, the age of onset of AAP is 
delayed as compared with FAP[5,9], adenomas seem 
more prevalent in the proximal colon[18,19], to spare 
the rectum[20], and they tend to be flat[21,22], and 
sometimes also hyperplastic polyps and flat serrated 
adenomas are present[23]. The risk of developing 
cancer is not 100% as in classical FAP. Extracolonic 
manifestations [duodenal adenomas, periampullary 
carcinoma, desmoid tumors, osteomas, epidermoid 
cysts, congenital hypertrophy of the retinal pigmented 
epithelium (CHRPE), supernumerary teeth, thyroid 
carcinoma, and hepatoblastoma] seem less frequent 
than in FAP, though studies are very few on this 
topic[23,24].
As mentioned, genetic testing should be offered to 
patients with AAP. APC and MUTYH are the two genes 
most frequently involved in the pathogenesis of AAP. 
However, constitutional mutations of other known and 
unknown genes contribute to the AAP phenotype.
APC is a tumor-suppressor gene, located on the 
long arm of chromosome 5[25]. In classical FAP a 
mutated allele is inherited, the other allele is damaged 
or lost by a somatic event, and this allows the growth 
of adenomas. Then, other mutational events in other 
genes are required to push ahead the malignant 
transformation. Some correlations between the site 
of the mutations within the open reading frame of the 
gene and the clinical manifestations of the disease 
have been reported so far (the so-called genotype-
phenotype correlations)[26]. As far as AAP is concerned, 
the overall frequency of APC mutations is difficult 
to establish, however it can be estimated around 
10%-20% of patients with less than 100 adenomas[9]. 
In these cases, AAP (namely AFAP) is inherited as 
an autosomal dominant disease, as it happens for 
classical FAP. In AAP, we know that APC mutations are 
found mostly near the 5’ and 3’ ends of the gene, and 
sometimes on exon 9[7,26], but other regions of the 
gene can be mutated.
MUTYH is a base excision repair gene whose 
protein repairs oxidative damage to DNA[4]. Biallelic 
mutations of that gene cause CG-AT transversions 
in several other genes, including APC and RAS. The 
two most frequent mutations found in patients with 
AAP are Y179C and G396D, both missense[27]. Thus, 
MUTYH-associated polyposis (MAP) has a recessive 
pattern of inheritance, and it is particularly frequent 
in patients with less than 100 adenomas[28,29], 
though MUTYH mutations may be found also in a 
small fraction of patients with classical FAP and no 
APC mutation[28]. It can be estimated that MUTYH is 
mutated in 20%-40% of patients with AAP[12,29]. Mean 
age at diagnosis seems delayed, when compared with 
patients with APC mutations[30]. Mutations in one allele 
only of the MUTYH gene seem not to confer a higher 
risk of developing intestinal adenomatous polyposis. 
Recently, other genes that may be constitutionally 
mutated in intestinal polyposis syndromes, were found 
associated with the AAP phenotype. These genes, 
involved in DNA synthesis are polymerase D1 (POLD1) 
and polymerase E gene (POLE). Mutations in one of 
these genes cause the rare Polymerase Proofreading-
Associated Polyposis (PPAP)[14], which is inherited as 
an autosomal dominant trait. Mutations in these genes 
have been reported so far also for Lynch syndrome, 
and probably cause an excess also of brain tumors[31].  
Constitutional mutations in other genes may 
explain a certain fraction of AAP: NTHL1[32], MSH3[33], 
FOCAD[34], POLD3 or other polymerase genes[35]. In 
the near future, other genes will be discovered in the 
germline of patients with AAP.
No established guidelines exist for the manage-
ment of AAP. When a mutation is found in APC or 
MUTYH (biallelic), a colonoscopy should be carried 
out, beginning at puberty, along with esophago-
gastroduodenoscopy, and repeated over time every 2-3 
years, and then regularly. However, since the genetic 
test is often negative for constitutional mutation, 
management is empirical and based on clinical findings 
in most cases. The choice of following a patient 
endoscopically or with a surgical approach is a matter 
of debate. The more convenient program is to continue 
an endoscopic follow-up when all polyps can be 
removed during colonoscopy, and to counsel surgery 
when the number of polyps is high or with multiple 
diminutive polyps, or in case of low compliance, 
or when a severe dysplasia or cancer is found at 
histological examination in one or more polyps[8,36]. 
When surgery is necessary, and the rectum is spared 
by polyps, a subtotal colectomy with ileo-rectal 
anastomosis is the treatment of choice[37]. Sometimes, 
when a severe phenotype (profuse polyposis) is 
present, due to mutations in particular zones of the 
genes, the surgical resection should be enlarged[38,39]. 
At variance with FAP, no valuable information is 
available for chemoprevention with non-steroidal anti-
inflammatory or other drugs in AAP, though the smaller 
number of polyps might be an advantage. Surveillance 
for upper gastrointestinal lesions (gastric polyps and 
duodenal/jejunal adenomas) with gastroduodenoscopy 
may be recommended at lapses of time guided by the 
Spigelman’ stage of duodenal polyposis, as in FAP, but 
no data are available at the moment[8].
CONCLUSION
In conclusion, AAP is a poorly defined syndrome 
which deserves further research. It may be defined 
as the presence of 10-99 synchronous adenomas 
in the large bowel, when at least 50% of the polyps 
removed are adenomatous (otherwise other polyposis 
syndromes should be suspected). This definition has 
the advantage of simplicity, but it may include sporadic 
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multiple adenomas of the large bowel at an extreme, 
or FAP cases at the upper limit. AAP shows a milder 
phenotype than FAP, with an older age of onset of 
adenomas and cancer, and less frequent extracolonic 
manifestations. AAP may be diagnosed as a single 
case in a family or, less frequently, it may be present 
in other family members. In less than 50% of cases, it 
may be caused by APC or MUTYH mutations, referred 
to as APC-associated polyposis (AFAP), or MUTYH-
associated polyposis (MAP), respectively. Surveillance 
should rely on colonoscopy at regular intervals, 
with removal of adenomas and careful histological 
examination. If removal of all polyps is not possible or 
advanced lesions are observed, the surgical treatment 
is mandatory. With no doubt, we need further insights 
into the undefined and poorly understood issue of AAP. 
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